C07K 16/114
Lentivirus
Official title: Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
C07K16/114 (Lentivirus) appears on 858 US grants and 1,118 published applications in this corpus.
Search patents in C07K- Granted patents
- 858
- Published applications
- 1,118
- Assignees
- 548
- Inventors
- 1,908
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 1 | 0 |
| 1988 | 3 | 0 |
| 1989 | 5 | 0 |
| 1990 | 5 | 0 |
| 1991 | 4 | 0 |
| 1992 | 5 | 0 |
| 1993 | 10 | 0 |
| 1994 | 8 | 0 |
| 1995 | 6 | 0 |
| 1996 | 15 | 0 |
| 1997 | 32 | 0 |
| 1998 | 34 | 0 |
| 1999 | 26 | 0 |
| 2000 | 29 | 0 |
| 2001 | 29 | 4 |
| 2002 | 24 | 20 |
| 2003 | 20 | 34 |
| 2004 | 9 | 37 |
| 2005 | 12 | 28 |
| 2006 | 16 | 32 |
| 2007 | 12 | 29 |
| 2008 | 12 | 29 |
| 2009 | 21 | 29 |
| 2010 | 17 | 41 |
| 2011 | 10 | 41 |
| 2012 | 28 | 45 |
| 2013 | 19 | 40 |
| 2014 | 30 | 45 |
| 2015 | 23 | 53 |
| 2016 | 29 | 51 |
| 2017 | 25 | 47 |
| 2018 | 46 | 53 |
| 2019 | 42 | 56 |
| 2020 | 35 | 65 |
| 2021 | 54 | 60 |
| 2022 | 26 | 60 |
| 2023 | 34 | 58 |
| 2024 | 44 | 74 |
| 2025 | 33 | 52 |
| 2026 | 25 | 35 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Cell-receptor targeted exosomes6 Oct 2026US 12,751,930 B2City of Hope
- Immunostimulatory adjuvants6 Oct 2026US 12,752,000 B2Orionis Biosciences BV
- Anti-human immunodeficiency virus-1 antibodies and methods for uses thereof29 Sep 2026US 12,747,285 B2Grifols Diagnostic Solutions Inc.
- RNA encoding an antibody29 Sep 2026US 12,747,451 B2Cure Vac SE
- Rapid elicitation of broadly neutralizing bovine antibodies to HIV Env25 Aug 2026US 12,715,907 B2International AIDS Vaccine Initiative
- Tcr-mimic bispecific antibodies for hiv-11 Oct 2026US 2026/0297193 A1The Johns Hopkins University
- Novel methods of generating antibodies24 Sep 2026US 2026/0285952 A1Rutgers, The State University of New Jersey
- Therapeutic compounds and methods17 Sep 2026US 2026/0274914 A1Regents of the University of Minnesota
- Genetic engneering of b cell receptors and uses thereof in antigen-induced antibody secretion17 Sep 2026US 2026/0274916 A1Ramot at Tel-Aviv University Ltd.
- Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof17 Sep 2026US 2026/0274995 A1ModeX Therapeutics, Inc.
Most cited
By later US patents
- Anti-PD-L1 antibodies, compositions and articles of manufacture459US 8,217,149 B2Genentech, Inc. · 2012
- Cells producing antibody compositions with increased antibody dependent cytotoxic activity247US 6,946,292 B2Kyowa Hakko Kogyo Co., Ltd. · 2005
- Chimeric receptor genes and cells transformed therewith196US 8,211,422 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2012
- Multispecific chimeric receptors174US 6,103,521 ACell Genesys, Inc. · 2000
- Multivalent and multispecific binding proteins and their use144US 6,492,123 B1Medical Research Council · 2002